Wave Life Sciences, Inc. (WVE)Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
5.04 USD
-0.12
(-2.326%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 5.09 +0.05 (1.071%) ⇧ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:20 a.m. EDT
The investment case here is fundamentally broken despite the aggressive bullishness seen in the options chain. The company is hemorrhaging cash with negative free cash flow of nearly $129 million and operating cash flow of -$192 million. Revenue has collapsed by 74% year-over-year, and the business is generating negative gross margins, indicating a complete failure of its core commercial model. While the balance sheet currently holds with $490 million in cash, the burn rate suggests this liquidity will evaporate quickly without a turnaround. The massive call option activity reflects a high-risk gamble on a potential biotech catalyst or merger, not a sound investment thesis. For a traditional investor, this is a value trap where the market is pricing in a total loss of capital due to deteriorating fundamentals. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.055074 |
| AutoETS | 0.055112 |
| AutoARIMA | 0.055112 |
| MSTL | 0.057549 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 2.57 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.271 |
| Excess Kurtosis | -1.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.611 |
| Revenue per Share | 0.348 |
| Market Cap | 993,122,816 |
| Forward P/E | -4.23 |
| Beta | -1.29 |
| Previous Name | Wave Life Sciences Ltd. |
| Website | https://wavelifesciences.com |
As of Aug. 22, 2026, 1:20 a.m. EDT: Speculators are overwhelmingly bullish on the upside, evidenced by massive open interest in out-of-the-money calls (strikes $8, $10, $15, $22) compared to negligible put volume. The call chain shows significant positioning at strikes far above the current price, while put activity is minimal and concentrated near the money. This indicates a speculative bet on a sharp price rally rather than a hedge against downside risk.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.46361744 |
| Address1 | 733 Concord Avenue |
| All Time High | 56.0 |
| All Time Low | 1.16 |
| Ask | 7.5 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 2,995,840 |
| Average Daily Volume3 Month | 3,094,017 |
| Average Volume | 3,094,017 |
| Average Volume10Days | 2,995,840 |
| Beta | -1.287 |
| Bid | 4.27 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 2.762 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.04 |
| Current Ratio | 9.987 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.22 |
| Day Low | 5.03 |
| Debt To Equity | 9.611 |
| Display Name | Wave Life Sciences |
| Earnings Call Timestamp End | 1,785,414,600 |
| Earnings Call Timestamp Start | 1,785,414,600 |
| Earnings Timestamp | 1,785,414,600 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | -214,520,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.546 |
| Enterprise To Revenue | 8.354 |
| Enterprise Value | 546,110,784 |
| Eps Current Year | -1.10928 |
| Eps Forward | -1.19055 |
| Eps Trailing Twelve Months | -1.05 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.7604 |
| Fifty Day Average Change | -0.72039986 |
| Fifty Day Average Change Percent | -0.12506074 |
| Fifty Two Week Change Percent | -46.361744 |
| Fifty Two Week High | 21.73 |
| Fifty Two Week High Change | -16.689999 |
| Fifty Two Week High Change Percent | -0.76806253 |
| Fifty Two Week Low | 5.01 |
| Fifty Two Week Low Change | 0.029999733 |
| Fifty Two Week Low Change Percent | 0.00598797 |
| Fifty Two Week Range | 5.01 - 21.73 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,447,252,200,000 |
| Float Shares | 94,573,272 |
| Forward Eps | -1.19055 |
| Forward P E | -4.2333374 |
| Free Cashflow | -128,778,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 317 |
| Fullday Change | -0.12 |
| Fullday Change Percent | -2.32558 |
| Fullday Price | 5.094 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -2.02001 |
| Gross Profits | -132,050,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15505 |
| Held Percent Institutions | 0.85603 |
| Implied Shares Outstanding | 197,048,175 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Wave Life Sciences, Inc. |
| Market | us_market |
| Market Cap | 993,122,816 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_256557334 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-29 |
| Net Income To Common | -202,472,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,016,768,583 |
| Number Of Analyst Opinions | 16 |
| Open | 5.17 |
| Operating Cashflow | -191,576,992 |
| Operating Margins | -32.48327 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 617 949 2900 |
| Post Market Change | 0.0539999 |
| Post Market Change Percent | 1.0714266 |
| Post Market Price | 5.094 |
| Post Market Time | 1,787,961,561 |
| Prev Name | Wave Life Sciences Ltd. |
| Previous Close | 5.16 |
| Price Eps Current Year | -4.5434875 |
| Price Hint | 2 |
| Price To Book | 1.8247646 |
| Price To Sales Trailing12 Months | 15.192101 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.672 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.125 |
| Region | US |
| Regular Market Change | -0.12 |
| Regular Market Change Percent | -2.32558 |
| Regular Market Day High | 5.22 |
| Regular Market Day Low | 5.03 |
| Regular Market Day Range | 5.03 - 5.22 |
| Regular Market Open | 5.17 |
| Regular Market Previous Close | 5.16 |
| Regular Market Price | 5.04 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 2,223,926 |
| Return On Assets | -0.33601 |
| Return On Equity | -0.67417 |
| Revenue Growth | -0.739 |
| Revenue Per Share | 0.348 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 197,048,175 |
| Shares Percent Shares Out | 0.082200006 |
| Shares Short | 16,200,874 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 16,848,760 |
| Short Name | Wave Life Sciences, Inc. |
| Short Percent Of Float | 0.1014 |
| Short Ratio | 5.75 |
| Source Interval | 15 |
| State | MA |
| Symbol | WVE |
| Target High Price | 42.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 19.0625 |
| Target Median Price | 15.0 |
| Total Cash | 490,601,984 |
| Total Cash Per Share | 2.49 |
| Total Debt | 43,590,000 |
| Total Revenue | 65,371,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.05 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.37315 |
| Two Hundred Day Average Change | -4.33315 |
| Two Hundred Day Average Change Percent | -0.4622939 |
| Type Disp | Equity |
| Volume | 2,223,926 |
| Website | https://wavelifesciences.com |
| Zip | 2,138 |